Literature DB >> 15990500

Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications.

P J Weiden1, A L Miller.   

Abstract

As a class, the newer antipsychotics are less likely to cause EPS but continue to have a range of other, non-EPS, side effects. Most standardized scales for side effects of antipsychotics emphasize the physical findings of the motor abnormalities of extrapyramidal symptoms (EPS). There is a need for screening instruments that include both EPS and non-EPS side effects. This article discusses the development of a screening instrument called the Approaches to Schizophrenia Communication (ASC). Initially derived from other subjective screening measures, the ASC was specifically designed to address the following issues pertaining to side effect evaluation of antipsychotics: 1) to cover all common and distressing side effects from antipsychotics, not just EPS, and 2) to screen for perceived distress, rather than the objective severity of the side effect. These two characteristics of the ASC make it possible for it to be given directly to the patient (the ASC Self-Report Version) or to be administered by mental health clinicians who do not have to be extensively trained in side-effect assessments (the ASC Clinician Interview version).

Entities:  

Year:  2001        PMID: 15990500     DOI: 10.1097/00131746-200101000-00005

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  19 in total

Review 1.  Lack of insight in schizophrenia: impact on treatment adherence.

Authors:  Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity.

Authors:  Zachary D Erickson; Crystal L Kwan; Hollie A Gelberg; Irina Y Arnold; Valery Chamberlin; Jennifer A Rosen; Chandresh Shah; Charles T Nguyen; Gerhard Hellemann; Dixie R Aragaki; Charles F Kunkel; Melissa M Lewis; Neena Sachinvala; Patrick A Sonza; Joseph M Pierre; Donna Ames
Journal:  J Gen Intern Med       Date:  2017-04       Impact factor: 5.128

3.  Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

Authors:  Wlodzimierz K Chrzanowski; Ronald N Marcus; Anne Torbeyns; Margaretta Nyilas; Robert D McQuade
Journal:  Psychopharmacology (Berl)       Date:  2006-10-21       Impact factor: 4.530

4.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

5.  Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Authors:  Susan M Essock; Nina R Schooler; T Scott Stroup; Joseph P McEvoy; Ingrid Rojas; Carlos Jackson; Nancy H Covell
Journal:  Am J Psychiatry       Date:  2011-05-02       Impact factor: 18.112

6.  Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Authors:  Nancy H Covell; Joseph P McEvoy; Nina R Schooler; T Scott Stroup; Carlos T Jackson; Ingrid A Rojas; Susan M Essock
Journal:  J Clin Psychiatry       Date:  2012-03-06       Impact factor: 4.384

7.  Real-world Data on Atypical Antipsychotic Medication Side Effects.

Authors:  Elisa Cascade; Amir H Kalali; Sagar Mehra; Jonathan M Meyer
Journal:  Psychiatry (Edgmont)       Date:  2010-07

Review 8.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

9.  Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial.

Authors:  Charlotte Hanlon; Girmay Medhin; Michael E Dewey; Martin Prince; Esubalew Assefa; Teshome Shibre; Dawit A Ejigu; Hanna Negussie; Sewit Timothewos; Marguerite Schneider; Graham Thornicroft; Lawrence Wissow; Ezra Susser; Crick Lund; Abebaw Fekadu; Atalay Alem
Journal:  Lancet Psychiatry       Date:  2022-01       Impact factor: 27.083

10.  Development of the My Medicines and Me (M3Q) side effect questionnaire for mental health patients: a qualitative study.

Authors:  Deena M Ashoorian; Rowan M Davidson; Daniel J T Rock; Liza J Seubert; Rhonda M Clifford
Journal:  Ther Adv Psychopharmacol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.